Erratum: Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy (Cancer Chemotherapy and Pharmacology (2013) 71:(893-904) (DOI 10.1007/s00280-013-2080-6);Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 893-904

  Du, Gangjun ^a   Yang, Yingming ^b   Zhang, Yaping ^a   Sun, Ting ^a   Liu, Weijie ^a   Wang, Yingying ^a   Li, Jiahuan ^a   Zhang, Houyun ^b  

^a HENAN UNIVERSITY   (China)

^b Kaifeng Second People's Hospital   (China)

Author keywords

Advanced non small cell lung cancer; Chemotherapy response; Connexin 43; Survival; Thrombocytosis

Indexed keywords

CALCIUM; CARBOPLATIN; CISPLATIN; CONNEXIN 43; GEMCITABINE; HEMOGLOBIN; NAVELBINE; PACLITAXEL; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOSIS; TUMOR VOLUME; CHEMISTRY; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CONNEXIN 43; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THROMBOCYTOSIS;

MLCS; MLOWN;

EID: 84878860621     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2188-8     Document Type: Erratum

References (29)

1. Siegel R, Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Kim DN, Nam TK, Choe KS, Choy H (2012) Personalized combined modality therapy for locally advanced non-small cell lung cancer. Cancer Res Treat 44:74-84
3. Lee DS, Kim YS, Kang JH, Lee SN, Kim YK, Ahn MI, Han DH, Yoo IR, Wang YP, Park JG, Yoon SC, Jang HS, Choi BO (2011) Clinical responses and prognostic indicators of concurrent chemoradiation for non-small cell lung cancer. Cancer Res Treat 43:32-41
4. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR (2006) A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107:781-792 (Pubitemid 44232670)
5. Belbaraka R, Trédan O, Ray-Coquard I, Chvetzoff G, Bajard A, Pérol D, Ismaili N, Ismaili M, Errihani H, Bachelot T, Rebattu P (2010) Factors of interrupting chemotherapy in patients with advanced non-small-cell lung cancer. BMC Res Notes 3:164
6. Berghmans T, Paesmans M, Sculier JP (2011) Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 3:127-138
7. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64:98-104
8. Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J (2012) Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer - a pilot study. Folia Histochem Cytobiol 50:80-86
9. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7:e38150
10. Gibbs AR, Thunnissen FB (2001) Histological typing of lung and pleural tumours: third edition. J Clin Pathol 54:498-499 (Pubitemid 32642935)
11. Laird DW (2006) Life cycle of connexins in health and disease. Biochem J 394:527-543
12. Darr EA, Patel AD, Yu G, Komorowski Z, McCormick S, Tiwari R, Schantz SP, Geliebter J (2011) Reduced Cx43 gap junction plaque expression differentiates thyroid carcinomas from benign disease. Arch Otolaryngol Head Neck Surg 137:1161-1165
13. Sirnes S, Bruun J, Kolberg M, Kjenseth A, Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E, Rivedal E (2012) Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int J Cancer 131:570-581
14. Zhao W, Han HB, Zhang ZQ (2011) Suppression of lung cancer cell invasion and metastasis by connexin 43 involves the secretion of follistatin-like 1 mediated via histone acetylation. Int J Biochem Cell Biol 43:1459-1468
15. Plante I, Stewart MK, Barr K, Allan AL, Laird DW (2011) Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene 30:1681-1692
16. Yu SC, Xiao HL, Jiang XF, Wang QL, Li Y, Yang XJ, Ping YF, Duan JJ, Jiang JY, Ye XZ, Xu SL, Xin YH, Yao XH, Chen JH, Chu WH, Sun W, Wang B, Wang JM, Zhang X, Bian XW (2012) Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin. Stem Cells 30:108-120
17. Xu HT, Li QC, Zhang YX, Zhao Y, Liu Y, Yang ZQ, Wang EH (2008) Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells. Folia Histochem Cytobiol 46:315-321
18. Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ (2011) Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor. Sarcoma 2011:971050
19. Jinn Y, Inase N (2010) Connexin 43, E-cadherin, beta-catenin and ZO-1 expression, and aberrant methylation of the connexin 43 gene in NSCLC. Anticancer Res 30:2271-2278
20. Cakar B, Karaoglanoglu M, Sayici Y, Gonullu Demirag G, Yucel I (2011) The prognostic value of thrombocytosis in newly diagnosed lung cancer patients: a retrospective analysis. J BUON 16:677-681
21. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610-618
22. Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, Noh SH (2012) Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 38:562-567
23. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T (2009) Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res 29:2687-2690
24. Lin MS, Huang JX, Zhu J, Shen HZ (2012) Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 59:1687-1690
25. Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gómez H, Maffuz A, Rojas-Garcia P, Perez-Alvarez C, Rodriguez-Ramirez S, Rodriguez-Antezana E, Ramirez-Ramirez L (2012) Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res 43:305-311
26. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T (2008) Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg 7:613-615
27. Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130:2747-2760
28. Lamiche C, Clarhaut J, Strale PO, Crespin S, Pedretti N, Bernard FX, Naus CC, Chen VC, Foster LJ, Defamie N, Mesnil M, Debiais F, Cronier L (2012) The gap junction protein Cx43 is involved in the bone-targeted metastatic behaviour of human prostate cancer cells. Clin Exp Metastasis 29:111-122
29. Kargus S, Weber FE, Luebbers HT, Zemann W, Graetz KW, Kruse AL (2012) Pretreatment thrombocytosis: a prognostic marker for oral squamous cell carcinoma? Oral Maxillofac Surg 16:197-200